Sequent Scientific Ltd
Sequent Scientific Ltd (SEQUENT) last traded at ₹272, a market capitalisation of ₹11,959 crore, on a P/E of 54.0. Over the past 52 weeks the stock has ranged between ₹168 and ₹298. Sequent Scientific Ltd last reported results for the quarter ended Jun 2026, with sales of ₹946 crore and net profit of ₹79 crore. The next scheduled event is an other on 30 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Sequent Scientific Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sequent Scientific Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹946 cr, up 19.4% from ₹792 cr a year earlier. Net profit was ₹79 cr, up 113.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 369 | 774 | 402 | 792 | 850 | 858 | 920 | 946 |
| Expenses | 330 | 674 | 355 | 673 | 677 | 683 | 736 | 768 |
| Operating profit | 39 | 100 | 46 | 119 | 173 | 176 | 184 | 178 |
| OPM % | 11% | 13% | 12% | 15% | 20% | 20% | 20% | 19% |
| Other income | 0 | 4 | 1 | 6 | 6 | -27 | 16 | 8 |
| Interest | 14 | 21 | 15 | 20 | 18 | 17 | 15 | 13 |
| Depreciation | 17 | 58 | 16 | 56 | 59 | 59 | 60 | 62 |
| Profit before tax | 8 | 24 | 16 | 48 | 102 | 73 | 125 | 112 |
| Tax % | 20% | -71% | 36% | 24% | 29% | 34% | 47% | 29% |
| Net profit | 6 | 42 | 10 | 37 | 73 | 49 | 66 | 79 |
| EPS (₹) | 0.10 | 1.78 | 0.37 | 1.27 | 2.18 | 0.88 | 1.19 | 1.51 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sequent Scientific Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,362 | 1,413 | 1,421 | 1,370 | 3,007 | 3,420 | 3,575 |
| Operating profit | 212 | 109 | 12 | 61 | 387 | 653 | 711 |
| OPM % | 16% | 8% | 0.8% | 4.5% | 13% | 19% | 20% |
| Net profit | 104 | 45 | -122 | -30 | 16 | 225 | 267 |
| EPS (₹) | 3.84 | 1.65 | -4.86 | -1.44 | 0.93 | 4.06 | 5.76 |
TTM is the trailing twelve months to the most recent quarter.
Sequent Scientific Ltd growth and returns
- 10 Years
- 19%
- 5 Years
- 20%
- 3 Years
- 34%
- TTM
- 53%
- 10 Years
- 28%
- 5 Years
- 15%
- 3 Years
- 73%
- TTM
- 148%
- 10 Years
- 8%
- 5 Years
- 4%
- 3 Years
- 45%
- 1 Year
- 56%
- 10 Years
- 8%
- 5 Years
- 3%
- 3 Years
- 4%
- Last Year
- 7%
Sequent Scientific Ltd shareholding pattern
Promoters held 61.31% at Jun 2026, up from 52.61% at Jun 2025. FIIs 4.50% and DIIs 3.76%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 52.76% | 52.61% | 52.61% | 52.61% | 52.33% | 61.41% | 61.31% | 61.31% |
| FIIs | 6.45% | 6.10% | 6.05% | 6.15% | 5.90% | 3.16% | 2.94% | 4.50% |
| DIIs | 9.99% | 12.01% | 12.82% | 12.98% | 12.91% | 7.36% | 7.98% | 3.76% |
| Public | 30.63% | 29.12% | 28.36% | 28.10% | 28.69% | 27.97% | 27.67% | 30.34% |
| No. of shareholders | 1,54,603 | 1,62,574 | 1,58,152 | 1,47,320 | 1,44,085 | 1,34,194 | 1,27,446 | 1,28,367 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Sequent Scientific Ltd events
The next scheduled event is an other on 30 Aug 2026.
- OtherConversion of intercompany loan to equity in subsidiary AAHL
See the full results calendar for every Indian company reporting in the next 30 days.
Sequent Scientific Ltd corporate filings
- Earning call Transcript Q1 FY 2026-27Company Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited delivered a robust Q1 FY27, with revenue from operations…
Read the full analysis - Audio Recording of Earnings call pertaining to the unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Viyash Scientific Limited has formally disclosed the audio recording of its earnings…
Read the full analysis - Newspaper Publication for Financial Results of Q1 FY 27.Company Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited (formerly Sequent Scientific Limited) reported robust financial…
Read the full analysis - Investor Presentation Q1 FY 2026-2027Company Updatehigh impact
Cruxal's analysis: Viyash Scientific Limited delivered a robust Q1 FY27 performance, reporting revenue of…
Read the full analysis - Voting results and scrutinizer ReportAGM/EGMlow impact
Cruxal's analysis: Viyash Scientific Limited has successfully concluded its 41st Annual General Meeting held…
Read the full analysis - Outcome of the 41st AGM held on August 11, 2026AGM/EGMlow impact
Cruxal's analysis: Viyash Scientific Limited successfully conducted its 41st Annual General Meeting on…
Read the full analysis - Press Release for Q1 FY 2026-27Company Updatelow impact
Cruxal's analysis: Viyash Scientific Ltd has issued a press release regarding its financial performance for…
Read the full analysis - Allotment of ESOP under Viyash Scientific Limited -Employee Stock Option Scheme 2026Company Updatelow impact
Cruxal's analysis: Viyash Scientific Limited has executed an allotment of equity shares pursuant to the…
Read the full analysis - Unaudited Financial Results for Q1 FY 2026-2027Resulthigh impact
Cruxal's analysis: Viyash Scientific Limited reported Q1 FY27 consolidated revenue of 946.36 crore and a net…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sequent Scientific Ltd
Cruxal reads every Sequent Scientific Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.